On November 30, 2021 Nektar Therapeutics (NASDAQ: NKTR) reported that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology programs: IL-2 agonist, bempegaldesleukin (BEMPEG), and IL-15 agonist, NKTR-255 (Press release, Nektar Therapeutics, NOV 30, 2021, View Source [SID1234596299]). The company will be presenting clinical data for BEMPEG from the ongoing PROPEL study in patients with non-small cell lung cancer (NSCLC) at the 2021 European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress in Geneva, Switzerland from December 8 to December 11, 2021. In addition, two clinical data presentations for NKTR-255 in patients with relapsed/refractory hematologic malignancies will be presented during the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting in Atlanta, Georgia from December 11 to December 14, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation at 2021 ESMO (Free ESMO Whitepaper)-IO:
Abstract #140P: "Preliminary results from PROPEL: A phase 1/2 study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC," Felip, E., et al.
ePoster will be on display on the ESMO (Free ESMO Whitepaper)-IO 2021 virtual meeting platform on Monday, December 6, 2021, at 12:00 pm GMT (7:00 a.m. ET)
Presentations at ASH (Free ASH Whitepaper)
Abstract #3134: "Safety, Tolerability, PK/PD, and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies," Shah, N., et al.
Presenter: Nina Shah, M.D.
Session 203: Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III
ePoster will be on display on the ASH (Free ASH Whitepaper) 2021 virtual meeting platform on Monday, December 13, 2021, at 6:00 a.m. ET
Abstract #2815: "Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T cells: Preliminary results from a Phase 1 Study," Turtle, C., et al.
Presenter: Alexandre Hirayama, M.D.
Session 704: Cellular Immunotherapies: Clinical: Poster II
ePoster will be on display on the ASH (Free ASH Whitepaper) 2021 virtual meeting platform on Sunday, December 12, 2021, at 6:00 a.m. ET
Company to Host Webcast Analyst and Investor Conference Call During ESMO (Free ESMO Whitepaper)-IO Congress 2021
The company will host a conference call and webcast for analysts and investors on Monday, December 6, 2021, at 1:00 p.m. GMT (8:00 a.m. ET) during the 2021 ESMO (Free ESMO Whitepaper)-IO Congress. The call will include Dr. Daniel Johnson, medical oncologist at the Gayle and Tom Benson Cancer Center and Deputy Director, Precision Cancer Therapies (Phase I) Research Program at Ochsner Medical Center, and Dr. Mehmet Altan, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
The event will follow the publication of the NKTR-214 (BEMPEG) PROPEL poster (Abstract #140P) on Monday, December 6, 2021.
Analyst Call:
Date and Time: Monday, December 6, 2021, at 1:00 p.m. GMT (8:00 a.m. ET)
Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (enter access code 7797059)
Investors and analysts can also view slides and listen to the live audio webcast of the presentation at View Source The event will also be available for replay for two weeks on the company’s website, www.nektar.com.
Biography for Daniel Johnson, M.D.
Daniel Johnson, M.D. is a medical oncologist at Ochsner Medical Center who specializes in treating patients with melanoma, lung cancer, and head and neck cancer. His specific research interests include strategies to overcome immunotherapy resistance and prevent immunotherapy related toxicities. He has published multiple peer-reviewed articles and presentations at national meetings pertaining to the management and underlying mechanisms of immune toxicity. Dr. Johnson is also a clinical investigator focusing on designing and implementing clinical trials intended to optimize the safety and efficacy of immune checkpoint inhibitors. Dr. Johnson received his M.D. from Louisiana State University (LSU) School of Medicine. He completed his internship and residency at LSU Internal Medicine Residency Program and completed his fellowship in hematology and medical oncology at the University of Texas MD Anderson Cancer Center. Dr. Johnson is board-certified in medical oncology and hematology by American Board of Internal Medicine.
Biography for Mehmet Altan, M.D.
Mehmet Altan, M.D., is an Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. His current research areas include identification of mechanisms for primary and secondary resistance to immunotherapies and predictive markers for immunotherapy toxicities. He also works on translational research projects for identification of spatiotemporal dynamics of the tumor microenvironment in response to immunotherapy to define potential therapeutic targets.